Abbott India Analyst Review May 2026
- May 16, 2026
- Posted by: Kashish Aggarwal
- Category: News
This Abbott India analyst review for May 2026 covers the key data investors need for ABBOTINDIA at its current price of Rs 29,000. Abbott India (NSE: ABBOTINDIA) is a subsidiary of Abbott Laboratories USA with a market capitalisation of approximately Rs 62,000 crore, marketing branded formulations in thyroid, gastroenterology, women’s health, and neurology. The analyst consensus target of Rs 32,000 implies meaningful upside from current levels, and this article examines the technical levels, business performance, valuation, and key risks that will determine whether ABBOTINDIA achieves that target through FY27.
Click Here – Get Free Investment Predictions
Abbott India Company Snapshot May 2026
Abbott India’s premium branded formulations (Thyronorm, Creon, Duphaston) command strong doctor relationships and pricing power. The company pays consistent dividends and has a debt-free balance sheet. The table below summarises the key data referenced in this Abbott India analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | ABBOTINDIA |
| Sector | Pharmaceuticals |
| CMP (May 2026) | Rs 29,000 |
| 52 Week High | Rs 32,000 |
| 52 Week Low | Rs 24,000 |
| Market Cap | Rs 62,000 Crore |
| Trailing P/E | 42.00x |
| Analyst Consensus Target | Rs 32,000 |
| Bull Case Target | Rs 38,000 |
| Bear Case Target | Rs 23,000 |
Analyst Insight in This Abbott India Analyst Review
Senior Research Analyst Ankit Jaiswal flags Abbott India as a stock to watch in May 2026. At Rs 29,000, Ankit Jaiswal notes that the key levels for ABBOTINDIA include support in the Rs 24,480 to Rs 27,550 band and resistance near Rs 30,740. He suggests watching Abbott India for a potential move toward the consensus target of Rs 32,000, contingent on Pharmaceuticals sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this Abbott India analyst review and does not constitute a trade recommendation.
Technical Analysis in This Abbott India Analyst Review
At Rs 29,000, ABBOTINDIA is trading within its 52-week band of Rs 24,000 to Rs 32,000. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.
Near-term support is identified in the Rs 24,480 to Rs 27,550 band while resistance is seen in the Rs 30,740 to Rs 30,500 zone. A sustained move above Rs 30,740 could open the path toward the analyst consensus of Rs 32,000.
Screen the best stocks on the Univest Screener.
Key Support and Resistance Levels
- Support Zone: Rs 24,480 to Rs 27,550 – investors tracking this Abbott India analyst review should watch for a stabilisation or bounce in this range as a potential accumulation signal.
- Resistance Zone: Rs 30,740 to Rs 30,500 – a sustained close above Rs 30,740 would be a positive breakout signal worth flagging.
- Medium-Term Target: The analyst consensus of Rs 32,000 represents the base-case upside for this Abbott India analyst review.
Business Segment Analysis
Women’s Health (Duphaston, Duphastonlib)
This is the primary revenue and margin driver for Abbott India, directly supporting the earnings trajectory toward the consensus target of Rs 32,000.
Thyroid and Metabolic Disorders (Thyronorm – Market Leader)
This segment adds scale and diversification to Abbott India’s business model and is a meaningful EPS contributor through FY27 and FY28.
Gastroenterology (Creon) and Neurology
This represents the medium-term growth frontier for Abbott India and a key re-rating catalyst for the stock over the next 12 to 24 months.
Valuation in This Abbott India Analyst Review
At Rs 29,000, Abbott India trades at a trailing P/E of 42.00x. This Abbott India analyst review presents three scenarios: a bull case of Rs 38,000 on strong earnings delivery, a base case of Rs 32,000 at consensus, and a bear case of Rs 23,000 if macro headwinds persist. Q1 FY27 results will be the first key validation point.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 38,000 | Strong earnings and sector tailwinds |
| Base Case (Consensus) | Rs 32,000 | Moderate growth, analyst consensus estimate |
| Bear Case | Rs 23,000 | Earnings miss or macro headwinds |
Trade Outlook for Abbott India
Based on the technical and fundamental analysis in this Abbott India analyst review, investors might watch ABBOTINDIA near the support zone of Rs 24,480 to Rs 27,550 for potential opportunities. A flag above Rs 30,740 could suggest improving momentum toward Rs 32,000. This article uses watch-and-flag language only and does not constitute a trade recommendation.
Key Risks for Abbott India in FY27
A well-rounded Abbott India analyst review must assess downside risks. Key risks for Abbott India include a macro slowdown affecting Pharmaceuticals sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in ABBOTINDIA.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Abbott India Analyst Review Verdict for 2026
This Abbott India analyst review concludes that at Rs 29,000, ABBOTINDIA offers a defined risk-reward with a consensus target of Rs 32,000. The 52-week range of Rs 24,000 to Rs 32,000 provides context on the current entry point. Use this Abbott India analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on ABBOTINDIA.
Frequently Asked Questions: Abbott India Analyst Review 2026
What is the analyst target for Abbott India in 2026?
The analyst consensus target is Rs 32,000, with a bull case of Rs 38,000 and a bear case of Rs 23,000. Monitor Q1 FY27 earnings for confirmation.
Is Abbott India a good investment at Rs 29,000?
At Rs 29,000 with a P/E of 42.00x and a consensus target of Rs 32,000, this Abbott India analyst review is constructive for medium to long-term investors in the Pharmaceuticals sector. Always consult a SEBI-registered advisor before investing.
What is Abbott India’s 52-week high and low?
The 52-week high is Rs 32,000 and the 52-week low is Rs 24,000. At Rs 29,000, ABBOTINDIA is positioned within this range as noted in this Abbott India analyst review.
What are the key risks for Abbott India?
Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals sector.
Where can I get live data and analyst targets for Abbott India?
Track Abbott India’s live price and analyst targets on the Univest Screener alongside professional financial advice.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
